PMID- 10073559
OWN - NLM
STAT- MEDLINE
DCOM- 19990316
LR  - 20071115
IS  - 0093-7754 (Print)
IS  - 0093-7754 (Linking)
VI  - 26
IP  - 1
DP  - 1999 Feb
TI  - Stage-specific application of allogeneic and autologous marrow transplantation in 
      the management of acute myeloid leukemia.
PG  - 21-34
AB  - Allogeneic (alloBMT) and autologous bone marrow transplantation (ABMT) have 
      become standard approaches for the management of adults with acute myeloid 
      leukemia (AML). The indications for transplantation remain controversial as 
      parallel improvements in intensive chemotherapy have resulted in excellent 
      outcomes for many patients. AlloBMT is the therapy of choice for patients who 
      fail to respond to induction chemotherapy. For those patients in first remission 
      (CRI), a policy of intensive postremission chemotherapy with transplantation upon 
      relapse appears to be optimal. There are no data to support transplantation in 
      CRI, allogeneic or autologous, for those patients with leukemia characterized by 
      favorable cytogenetic abnormalities [ie, core-binding factor type or t(15;17)], 
      as these patients do well with nonmyeloablative strategies. Patients with 
      relapsed disease appear to be best served with allogeneic transplantation from a 
      human leukocyte antigen (HLA)-matched sibling or one-antigen-mismatched family 
      member, whereas for those patients lacking a related donor, unrelated donor 
      alloBMT or ABMT provides similar long-term overall survival. Randomized studies 
      for the optimal management of relapsed disease are lacking but are needed. The 
      objective of this review is to discuss the data supporting the use of alloBMT or 
      ABMT at various points during the course of de novo adult AML.
FAU - Edenfield, W J
AU  - Edenfield WJ
AD  - Hematology/Oncology Service, Walter Reed Army Medical Center, Washington, DC, 
      USA.
FAU - Gore, S D
AU  - Gore SD
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Semin Oncol
JT  - Seminars in oncology
JID - 0420432
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - Adult
MH  - Antineoplastic Agents/*adverse effects
MH  - *Bone Marrow Transplantation/methods
MH  - Clinical Trials as Topic
MH  - Humans
MH  - Leukemia, Myeloid, Acute/drug therapy/*pathology/*therapy
MH  - Neoplasm Staging
MH  - Prospective Studies
MH  - Transplantation, Autologous
MH  - Transplantation, Homologous
MH  - Treatment Outcome
RF  - 112
EDAT- 1999/03/12 00:00
MHDA- 1999/03/12 00:01
CRDT- 1999/03/12 00:00
PHST- 1999/03/12 00:00 [pubmed]
PHST- 1999/03/12 00:01 [medline]
PHST- 1999/03/12 00:00 [entrez]
PST - ppublish
SO  - Semin Oncol. 1999 Feb;26(1):21-34.